Medical economics

German vaccine maker CureVac surges almost 250% in Nasdaq debut

Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering.

page 34 from 40